NEW YORK (GenomeWeb) – DxTerity Diagnostics announced on Tuesday that it has arranged to receive up to $7.5 million in term debt financing from SWK Funding, a subsidiary of SWK Holdings.

The firm said it will use the proceeds toward the commercialization of its DxDirect genomics testing platform and DxCollect MicroCollection Device (MCD).

The firm's proprietary chemistry, DxDirect, enables multiplexed genomic testing directly from the patient sample. The DxCollect MCD allows for the stabilization and transport of blood RNA collected from a finger or heel prick.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.